These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 29302338)

  • 1. Regenerative medicine funding policies in Europe and The Netherlands.
    de Haan G; de Crom R; Dzierzak E; Mummery C
    NPJ Regen Med; 2017; 2():1. PubMed ID: 29302338
    [No Abstract]   [Full Text] [Related]  

  • 2. Industry perceptions of barriers to commercialization of regenerative medicine products in the UK.
    Plagnol AC; Rowley E; Martin P; Livesey F
    Regen Med; 2009 Jul; 4(4):549-59. PubMed ID: 19580404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opinions and potential solutions regarding dissemination bias from funding agencies of biomedical research in Europe.
    Pardo-Hernandez H; Urrútia G; Meerpohl JJ; Marušić A; Wager E; Bonfill X;
    J Eval Clin Pract; 2018 Feb; 24(1):72-79. PubMed ID: 28090730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent public policies in The Netherlands to control pharmaceutical pricing and reimbursement.
    Rigter H
    Pharmacoeconomics; 1994; 6 Suppl 1():15-21. PubMed ID: 10155581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Netherlands advancing to the forefront of regenerative medicine.
    Gielen K
    Stem Cells Dev; 2014 Dec; 23 Suppl 1():29-31. PubMed ID: 25457958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Migration in the Netherlands: policies and models.
    Drewe P
    Delft Prog Rep; 1977; 2():343-69. PubMed ID: 12263014
    [No Abstract]   [Full Text] [Related]  

  • 7. Enabling personalized medicine in Europe by the European Commission's funding activities.
    Nimmesgern E; Norstedt I; Draghia-Akli R
    Per Med; 2017 Jul; 14(4):355-365. PubMed ID: 29749834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Targeted public funding for health research in the Netherlands].
    Viergever RF; Hendriks TC
    Ned Tijdschr Geneeskd; 2014; 159():A8174. PubMed ID: 25589280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular research funding in Europe: The Netherlands. Interview by Jennifer Taylor.
    Doevendans P
    Circulation; 2008 Feb; 117(6):f31-3. PubMed ID: 18268157
    [No Abstract]   [Full Text] [Related]  

  • 10. Invisible Europeans: sexual citizenship in the new Europe.
    Binnie J
    Environ Plan A; 1997 Feb; 29(2):237-48. PubMed ID: 12292252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Turning Regenerative Medicine Breakthrough Ideas and Innovations into Commercial Products.
    Bayon Y; Vertès AA; Ronfard V; Culme-Seymour E; Mason C; Stroemer P; Najimi M; Sokal E; Wilson C; Barone J; Aras R; Chiesi A
    Tissue Eng Part B Rev; 2015 Dec; 21(6):560-71. PubMed ID: 26179129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Choice policies in Northern European health systems.
    Vrangbaek K; Robertson R; Winblad U; Van de Bovenkamp H; Dixon A
    Health Econ Policy Law; 2012 Jan; 7(1):47-71. PubMed ID: 22221928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Funding for public health in Europe in decline?
    Rechel B
    Health Policy; 2019 Jan; 123(1):21-26. PubMed ID: 30509874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nutrition policies in western Europe: national policies in Belgium, The Netherlands, France, Ireland, and the United Kingdom.
    James WP; Ralph A; Bellizzi M
    Nutr Rev; 1997 Nov; 55(11 Pt 2):S4-20. PubMed ID: 9420457
    [No Abstract]   [Full Text] [Related]  

  • 15. Generic Medicine Pricing Policies in Europe: Current Status and Impact.
    Dylst P; Simoens S
    Pharmaceuticals (Basel); 2010 Mar; 3(3):471-481. PubMed ID: 27713264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abortion, 1973: some recent world events in relation to pregnancy termination.
    Trans Aust Med Congr; 1974 Jun; 1(5):27-30. PubMed ID: 12333737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National population policies in industrial countries: praxis or paradox?
    Leeuw F; Van De Vall M
    Comp Soc Res; 1984; 7():351-68. PubMed ID: 12340265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endangerment of the iPSC stock project in Japan: on the ethics of public funding policies.
    Akabayashi A; Nakazawa E; Jecker NS
    J Med Ethics; 2018 Oct; 44(10):700-702. PubMed ID: 30087154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insurance systems and reimbursement concerning research and development of regenerative medicine in Japan.
    Okada K; Miyata T; Sawa Y
    Regen Med; 2017 Mar; 12(2):179-186. PubMed ID: 28244828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Research and policy with regard to ethnic minorities in the Netherlands: an historical outline and the state of affairs.
    Penninx R
    Int Migr; 1984; 22(4):345-66. PubMed ID: 12159636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.